drugset / Trial / NCT05602493

A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction

NCT05602493

Phase 3 Active not recruiting 60 enrolled Xeolas Pharmaceuticals Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine the efficacy and safety of the effects of a topical medication on bone remodeling after dental extraction, in order to establish whether such treatment can be a new therapeutic option for said pathology. The participation of 60 patients is expected, who will be divided randomly in equal proportions into two groups. Treatment groups: Group A (30 patients): medication administered topically. Group B (30 patients): placebo with characteristics equal to the drug under investigation.

Timeline

Start
2022-11-22
Primary completion
2024-10-20
Completion
2024-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 0.7 mg/ml Topical

Indications